Clinical Trial Patient Retention

Clinical Trial Patient Retention banner

As many as 30% of subjects in Phase 3 studies drop out*. Gruelling schedules, costly travel and tardy reimbursement are all factors in these high dropout rates, causing delays or even cancellations in a trial. It is crucial to keep subjects motivated, and part of this can be achieved through efficient management of travel and other expenses.

Specialised clinical trials travel services were developed more than a decade ago. The demand for these services grew as it became apparent that CROs were struggling to manage travel and expenses for their trial subjects. Confidentiality rules and regulations stipulated by regulatory bodies, such as the FDA and EMA, meant that the sponsor could not access specific information on participants, and this in turn made it extremely difficult to arrange the reimbursement of travel costs and other expenses with the subjects.

The solution was that a travel management company (TMC) would intervene between the investigating site and the sponsor and, as they are classed as independent organisations, participants were given the choice as to whether to use this service or not. And those who did were able to contact the service provider directly. As the service is optional and operated in conjunction with preapproved travel and expense guidelines, institutional review boards (IRBs) are satisfied that the subjects are not being enticed to use the service.*Source International Clinical Trials.

Benefits at a Glance

• Serves as a liaison between the investigating site and the sponsor
• Satisfies the requirements of the review boards

Contact us now to find out more about Clinical Trial Patient Retention


Find out more

Find out more